Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression

Cancer Research

Volumn 68, Issue 23, 2008, Pages 9788-9798

  Aleku, Manuela ^a   Schulz, Petra ^a   Keil, Oliver ^a   Santel, Ansgar ^a   Schaeper, Ute ^a   Dieckhoff, Britta ^a   Janke, Oliver ^a   Endruschat, Jens ^a   Durieux, Birgit ^a   Röder, Nadine ^a   Löffler, Kathrin ^a   Lange, Christian ^a   Fechtner, Melanie ^a   Möpert, Kristin ^a   Fisch, Gerald ^a   Dames, Sibylle ^a   Arnold, Wolfgang ^a   Jochims, Karin ^b   Giese, Klaus ^a   Wiedenmann, Bertram ^a   Scholz, Arne ^a   Kaufmann, Jörg ^a,c   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b IASON Consulting   (Germany)

^c Silence Therapeutics GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATU 027; HEAT SHOCK PROTEIN 60; LIPOPLEX; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PROTEIN KINASE N3; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CANCER INHIBITION; CANCER MODEL; CELL MIGRATION; CELL PROLIFERATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL DELIVERY; LYMPH NODE METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIMATE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT;

ANIMALS; CELL GROWTH PROCESSES; DISEASE PROGRESSION; ENDOTHELIAL CELLS; HELA CELLS; HUMANS; LIPOSOMES; LYMPHATIC METASTASIS; MACACA FASCICULARIS; MALE; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; PROTEIN KINASE C; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 57149086661     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2428     Document Type: Article

References (47)

1. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007;59:75-86.
2. Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 2007;76:9-21.
3. Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett 2005;579:5996-6007.
4. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8:173-84.
5. Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006;13:1222-34.
6. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007;117:3623-32.
7. De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007;13:431-56.
8. Li SD, Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 2006;13:1313-9.
9. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92.
10. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:e149.
11. Pirollo KF, Rait A, Zhou Q, et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007;67:2938-43.
12. Li SD, Chen YC, Hackett MJ, Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 2008;16:163-9.
13. Santel A, Aleku M, Keil O, et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther 2006;13:1360-70.
14. Chien PY, Wang J, Carbonaro D, et al. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 2005;12:321-8.
15. Landen CN, Jr., Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-8.
16. Pal A, Ahmad A, Khan S, et al. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol 2005;26:1087-91.
17. Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 2006;112:229-39.
18. Aleku M, Fisch G, Mopert K, et al. Intracellular localization of lipoplexed siRNA in vascular endothelial cells of different mouse tissues. Microvasc Res 2008;76:31-41.
19. Leenders F, Mopert K, Schmiedeknecht A, et al. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J 2004;23:3303-13.
20. Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003;31:2705-16.
21. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84:951-7.
22. Fox SB, Harris AL. Histological quantitation of tumour angiogenesis. APMIS 2004;112:413-30.
23. Van der Auwera I, Cao Y, Tille JC, et al. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 2006;95:1611-25.
24. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-7.
25. Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 2004;10:143-5.
26. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003;31:1171-7.
27. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
28. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
29. Hamada K, Sasaki T, Koni PA, et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005;19:2054-65.
30. Graupera M, Guillermet-Guibert J, Foukas LC, et al. Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature 2008;453:662-6.
31. Ceteci F, Ceteci S, Karreman C, et al. Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer. Cancer Cell 2007;12:145-59.
32. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
33. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
34. Renyi-Vamos F, Tovari J, Fillinger J, et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 2005;11:7344-53.
35. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005;438:946-53.
36. Sundlisaeter E, Dicko A, Sakariassen PO, Sondenaa K, Enger PO, Bjerkvig R. Lymphangiogenesis in colorectal cancer-prognostic and therapeutic aspects. Int J Cancer 2007;121:1401-9.
37. Thelen A, Scholz A, Benckert C, et al. Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. Ann Surg Oncol 2008;15:791-9.
38. Caunt M, Mak J, Liang WC, et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008;13:331-42.
39. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
40. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9 Suppl 1: 2-10.
41. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
42. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008;319:195-8.
43. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 2006;80:1183-96.
44. Du R, Lu KV, Petritsch C, et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-20.
45. Kleinman ME, Yamada K, Takeda A, et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;425:591-7.
46. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006;13:494-505.
47. Kim JY, Choung S, Lee EJ, Kim YJ, Choi YC. Immune activation by siRNA/liposome complexes in mice is sequence-independent: lack of a role for Toll-like receptor 3 signaling. Mol Cells 2007;24:247-54.